$220M in Milestones per Target
Conjugate Reverb: Abbott Pays $25M to Broaden SeaGen Deal
By Randy Osborne
Wednesday, October 24, 2012
Despite sales of its approved antibody-drug conjugate (ADC) Adcetris at levels described by analysts as "flat," Seattle Genetics Inc. scored an expansion of the deal begun last year with Abbott. The arrangement brings $25 million up front in exchange for Abbott's right to use the auristatin-based ADC technology against more targets than before.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.